Karyopharm discloses 2026 cash retention program details for top executives

Karyopharm Therapeutics Inc. filed a Form 8-K disclosing that its board of directors, acting on recommendation of the Compensation Committee, implemented a retention program on July 13, 2026 covering certain employees, including the company's named executive officers and Chief Financial Officer, called the 2026 Leadership Cash Retention Program.¹

The company said the purpose of the program is to incentivize retention of key employees during a period in which the company is expecting several meaningful catalysts requiring their continued experience and expertise.¹ The filing also notes that the new program replaces previously guaranteed amounts under the company's Annual Bonus Plan for 2026.¹

Under the program, Richard Paulson, President and Chief Executive Officer, will receive $1,725,000.¹ Stuart Poulton, Executive Vice President, Chief Development Officer, will receive $640,000.¹ Dr. Reshma Rangwala, Executive Vice President, Chief Medical Officer and Head of Research, will receive $725,000.¹ Lori Macomber, Executive Vice President, Chief Financial Officer and Treasurer, will receive $625,000.¹

The awards carry conditions. Recipients may have to repay the funds if their employment is terminated for any reason other than by the company without cause, by the participant for good reason, or due to death or permanent disability, prior to the earlier of 12 months from the payment date or 30 days following a qualifying corporate event.¹ In addition, amounts paid under the program will reduce any amounts payable under previously agreed severance arrangements.¹

The 8-K was signed on July 17, 2026 by Michael Mano, Executive Vice President, Chief Legal Officer and Secretary.¹